Grants Search Results

Young adulthood is a time filled with exciting possibilities and also difficult challenges. People at this stage of life may be deciding on or attending school, selecting a career or working hard at their jobs, dating or in a relationship, and may be planning for or raising children. A cancer diagnosis does not fit into these plans and goals. Researchers are finding that the biology of the cancers in people of this age group are different, and increasing data indicates that adult patients with some cancers would benefit by being treated on what are traditionally pediatric therapies. Ochsner's Adolescent and Young Adult (AYA) Cancer and Survivor program is the first and only one of its kind in the region. The team is made up of professionals from pediatric and adult medicine. This program is designed for people between the ages of 15 and 39 years of age with cancer -newly diagnosed, actively in therapy and or cancer survivors. This grant supports a Nurse Coordinator who works with new patients in the combined AYA Cancer and Survivor Clinic, to ensure they have access to the best clinical trials for their cancer.

This grant supports a clinical research coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on immunotherapy clinical trials, often their best hope for a cure.

This grant supports a solid tumor research coordinator to ensure that more solid tumor patients can be treated on early phase clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Imaging presents a powerful tool by visualizing individual cells and cellular processes in great detail. However, it remains very challenging to obtain this detailed cellular information for entire tumors and surrounding tissue, which will be key for improving our understanding of cancer progression. To fulfil this need, Dr. Rios and colleagues have developed unique and innovative imaging strategies that can visualize individual cells and their specific behavior in an entire tissue or tumor specimen. She is applying this advanced three-dimensional (3D) imaging to study the underlying mechanisms of childhood cancer. For instance, they have been able to identify new tumor cell subsets that are now being analyzed for their role in tumor progression. In addition, she is studying the specific behavior and underlying mechanisms that allow tumor cells to invade their surrounding tissue, a key contributing factor to tumor aggressiveness. By applying these imaging technologies to address these and other unanswered questions in pediatric oncology, Dr. Rios hopes to identify novel targets for treating childhood cancer. The St. Baldrick’s Robert J. Arceci Innovation Award is given in honor of the late Dr. Robert Arceci. A pioneer in the field, this award reflects Dr. Arceci’s values including creativity, collaboration, and commitment to early- to mid-career scientists.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

This grant funded three projects. Project 1: A five-year study on Paediatric Hepatic International Tumour Trial (PHITT) in Hong Kong. Project 2: An extension of a parallel study with the Chinese children cancer group relapsed acute lymphoblastic leukemia 2017 Study (CCCG relapsed ALL 2017). Project 3: A New Clinical trial protocol for children with acute promyelocytic leukemia (APL) in Hong Kong.

This grant supports a Pediatric Neuro-Oncology Program Clinical Research Associate to ensure that more brain tumor patients can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Nurse to ensure that more kids can be treated on clinical trials, often their best hope for a cure. In the past, children diagnosed with cancer in the Rio Grande Valley had to travel to cities such as Houston or San Antonio to get state-or-the-art treatment through clinical trials. Physicians at the Vannie Cook Clinic in the Rio Grande Valley now have access to the most advanced trials and latest medications through Children's Oncology Group and other Texas-based clinical trials. This gives patients the opportunity to have the optimal outcome from their cancer therapy. More importantly, parents know that their child is getting the best care available, anywhere. That gives families hope that their child will live a long, healthy life.

This grant supports a research nurse coordinator to ensure that more Adolescent and Young Adult (AYA) patients can be treated on clinical trials, often their best hope for a cure.

This grant supports research associates to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Senior Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a research associate to ensure that more kids can be treated on early phase clinical trials, often their best hope for a cure.

This grant supports the Nurse Researchers in the UIC/Rush/Stroger COG Program to ensure more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports the creation of a Yale University Pediatric Hematology/Oncology tissue bank that will be used for current and future research projects involving the study of pediatric cancers. This repository will provide tissues for researchers seeking to study the biology, genetics and immunity of pediatric cancers. Establishment of this tissue bank will foster the ability of the institution to collaborate on more early phase clinical trials as well as to support discovery of new biomarkers to predict response to treatments.

This grant supports the Childhood Cancer Survivorship Program at Valley Children's Hospital, providing critical patient data for survivorship researchers.

Thanks to remarkable scientific advances, over 80% of children with cancer will become long-term survivors, but most survivors experience long-term side effects of treatment. Our research has found that parents want early information about long-term side effects of treatment starting at diagnosis, but unfortunately most parents do not receive the information they need. In this project, Dr. Greenzang and colleagues are building a website to help parents understand the long-term effects of their treatment choices. They will then use the website with parents who are making new treatment decisions to evaluate whether parents find the website clear and useful, and to assess if using it can improve parents' understanding of medical information, help parents make decisions about treatment, and help prepare parents for their children's long-term care.

Acute lymphoblastic leukemia (ALL) remains the most common cancer of children and young adults. Despite intensified treatments that achieved cure rates around 85%, there is a number of children who will relapse and succumb to therapy-resistant disease. One of the revolutions in the treatment of human cancer the last decade was immunotherapy, the ability of our own immune system to fight cancer. Unfortunately, despite its successes in a number of solid tumours, immunotherapy has not really impacted the treatment of leukemia, with the exception of CAR-T cell treatment of pediatric B-ALL. Indeed, some frequent types of pediatric ALL, and specifically T cell ALL (T-ALL) and its subtypes, have no immunotherapy treatment options. We believe that this is because we still don't understand how the cells of the immune system interact with the leukemia. Actually, researchers don't even know what type of immune cells are there available to fight the disease. Dr. Aifantis is applying a number of single cell techniques to create a map of the immune cells in the bone marrow of children with T-ALL. He is doing this at diagnosis of the disease, after treatment (remission) and when the children relapse. These studies will offer the first map of the immune system in pediatric ALL and will enable researchers to propose ways to activate the immune system to fight the tumour.